PriceTargets.com logo

Omeros - OMER Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$3.21 As of 04/18/2024 01:00 AM ET
▼ -0.13 (-3.89%)

This chart shows the closing price for OMER by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Omeros Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OMER and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OMER

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Omeros in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $3.21.

This chart shows the closing price for OMER for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 1 contributing investment analysts is to hold stock in Omeros. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/10/2023Cantor FitzgeraldDowngradeOverweight ➝ NeutralLow
7/10/2023Cantor FitzgeraldReiterated RatingOverweightLow
12/8/2022UBS GroupDowngradeBuy ➝ NeutralLow
11/10/2022Cantor FitzgeraldLower Target$20.00 ➝ $13.00Low
11/8/2022Bank of AmericaDowngradeNeutral ➝ Underperform$8.00 ➝ $3.00Low
6/8/2022Bank of AmericaDowngradeBuy ➝ Neutral$12.00 ➝ $4.00High
1/18/2022Cantor FitzgeraldLower Target$34.00 ➝ $20.00High
10/19/2021HC WainwrightLower TargetBuy$19.00 ➝ $12.00High
10/8/2021JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightMedium
10/6/2021HC WainwrightReiterated RatingBuy$32.00 ➝ $19.00Medium
10/1/2021WedbushDowngradeNeutral ➝ Underperform$5.00High
10/1/2021Maxim GroupDowngradeBuy ➝ HoldHigh
9/27/2021JPMorgan Chase & Co.Initiated CoverageNeutral$15.00High
9/7/2021HC WainwrightReiterated RatingBuy$32.00Low
6/18/2021WBB SecuritiesBoost TargetStrong-Buy$75.00 ➝ $100.00Medium
4/26/2021HC WainwrightLower TargetBuy$34.00 ➝ $32.00Medium
2/1/2021UBS GroupInitiated CoverageBuy$25.00Low
1/20/2021HC WainwrightBoost TargetBuy$31.00 ➝ $34.00High
1/4/2021HC WainwrightReiterated RatingBuy$32.00 ➝ $31.00N/A
12/4/2020Maxim GroupBoost TargetBuy$20.00 ➝ $25.00Low
11/23/2020HC WainwrightReiterated RatingBuy$32.00Medium
10/20/2020Bank of AmericaInitiated CoverageBuy$21.00High
9/1/2020WedbushLower TargetNeutral$17.00 ➝ $12.00High
8/21/2020HC WainwrightLower TargetBuy$34.00 ➝ $32.00High
8/14/2020Maxim GroupLower TargetBuy$25.00 ➝ $20.00Low
6/9/2020WedbushReiterated RatingHold$17.00Medium
5/12/2020Needham & Company LLCReiterated RatingHoldHigh
5/12/2020HC WainwrightReiterated RatingBuy$34.00High
4/27/2020WedbushReiterated RatingHold$17.00Low
3/4/2020WedbushReiterated RatingHold$18.00 ➝ $22.00Medium
3/3/2020HC WainwrightReiterated RatingBuy$34.00N/A
12/5/2019Maxim GroupReiterated RatingBuy$25.00Low
12/4/2019Needham & Company LLCReiterated RatingHoldHigh
12/2/2019HC WainwrightReiterated RatingBuy$35.00 ➝ $34.00Medium
11/15/2019WedbushReiterated RatingHold$18.00Low
11/13/2019Needham & Company LLCReiterated RatingHoldLow
11/5/2019HC WainwrightReiterated RatingBuy$35.00High
10/30/2019HC WainwrightReiterated RatingBuy$35.00High
10/28/2019WedbushReiterated RatingHold$18.00Low
9/18/2019HC WainwrightSet TargetBuy$35.00Low
8/9/2019Maxim GroupSet TargetBuy$32.00High
7/15/2019WedbushReiterated RatingNeutral$18.00Medium
5/28/2019HC WainwrightSet TargetBuy$35.00Medium
5/20/2019WedbushReiterated RatingHold$18.00Medium
5/6/2019Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$26.00Low
(Data available from 4/19/2019 forward)

News Sentiment Rating

0.11 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2023
  • 1 very positive mentions
  • 12 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
10/21/2023
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/19/2024
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2024
  • 2 very positive mentions
  • 23 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2024
  • 2 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
4/18/2024

Current Sentiment

  • 2 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Omeros logo
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction. In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $3.21
Low: $3.20
High: $3.41

50 Day Range

MA: $3.90
Low: $3.05
High: $4.89

52 Week Range

Now: $3.21
Low: $0.92
High: $7.80

Volume

429,130 shs

Average Volume

568,299 shs

Market Capitalization

$185.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.34

Frequently Asked Questions

What sell-side analysts currently cover shares of Omeros?

The following sell-side analysts have issued reports on Omeros in the last twelve months: Cantor Fitzgerald, and StockNews.com.
View the latest analyst ratings for OMER.

What is the current price target for Omeros?

0 Wall Street analysts have set twelve-month price targets for Omeros in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Omeros in the next year.
View the latest price targets for OMER.

What is the current consensus analyst rating for Omeros?

Omeros currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in OMER, but not buy more shares or sell existing shares.
View the latest ratings for OMER.

What other companies compete with Omeros?

Other companies that are similar to Omeros include Nektar Therapeutics, Lifecore Biomedical, Rigel Pharmaceuticals, Skye Bioscience and Organigram. Learn More about companies similar to Omeros.

How do I contact Omeros' investor relations team?

Omeros' physical mailing address is 201 ELLIOT AVENUE WEST, SEATTLE WA, 98119. The biopharmaceutical company's listed phone number is (206) 676-5000 and its investor relations email address is [email protected]. The official website for Omeros is www.omeros.com. Learn More about contacing Omeros investor relations.